Suchergebnisse - "Drug Repositioning"

PubPharm (14)

1

Development and Validation of a HPLC-MS/MS Method to Measure Nifuroxazide and Its Application in Healthy and Glioblastoma-Bearing Mice

enthalten in: Pharmaceutics | 2022

von Ceruti, T. | D'Alessandris, Q. | Frapolli, R. | +7

2

Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site

enthalten in: Pharmaceutics | 2022

von Suriya, U. | Mahalapbutr, P. | Rungrotmongkol, T.

3

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach

enthalten in: Pharmaceutics | 2022

von Kim, H. | Kim, J.

4

Evaluation of the Anti-Histoplasma capsulatum Activity of Indole and Nitrofuran Derivatives and Their Pharmacological Safety in Three-Dimensional Cell Cultures

enthalten in: Pharmaceutics | 2022

von Vaso, C. | Bila, N. | Pandolfi, F. | +12

5

Development and Validation of a HPLC–MS/MS Method to Measure Nifuroxazide and Its Application in Healthy and Glioblastoma-Bearing Mice

in: Pharmaceutics | 2022

von Tommaso Ceruti | Quintino Giorgio D’Alessandris | Roberta Frapolli | +7

6

Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site

in: Pharmaceutics | 2022

von Utid Suriya | Panupong Mahalapbutr | Thanyada Rungrotmongkol

7

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach

in: Pharmaceutics | 2022

von Hyeon-A Kim | Joo-Eun Kim

8

In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets : A Drug Repurposing Approach

enthalten in: Pharmaceutics | 2021

von Thirunavukkarasu, M. | Suriya, U. | Rungrotmongkol, T. | +1

9

Sustained-Release Microspheres of Rivoceranib for the Treatment of Subfoveal Choroidal Neovascularization

enthalten in: Pharmaceutics | 2021

von Kim, E. | Lee, M. | Jeong, H. | +9

10

Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19 : A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities

enthalten in: Pharmaceutics | 2021

von Xiang, Y. | Wong, K. | So, H.